FDA granted approval and accepted sNDA for Bristol-Myers Squibb drugs, alongside EMA validation and a collaboration agreement with Merck.
2 reports, 2 independent
Updated Jul 24
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted approval and accepted sNDA for Bristol-Myers Squibb drugs, alongside EMA validation and a collaboration agreement with Merck.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
- FDA
-
MRK
Visual artist and director.
Nothing else this week.
Related events
- The FDA is currently reviewing the supplemental New Drug Application (sNDA) for Arikayce's full product approval.
- Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- The FDA recommended advancement for a new drug application submitted by a company.
- Takeda announced FDA approval of its drug MIMRYLO, a decision supported by VERIFY results.
Coverage
Newest first; wire copies grouped- ZacksBristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock? Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The stock r
- Business WireBristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Global